EPA:ALINT - FR0010908723 - Common Stock
The current stock price of ALINT.PA is 0.27 EUR. In the past month the price decreased by -6.57%. In the past year, price decreased by -44.44%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 20.04 | 321.87B | ||
1ABBV.MI | ABBVIE INC | 19.56 | 314.07B | ||
AMG.DE | AMGEN INC | 12.95 | 130.47B | ||
1GILD.MI | GILEAD SCIENCES INC | 14.78 | 122.10B | ||
GIS.DE | GILEAD SCIENCES INC | 14.72 | 121.28B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 23.57 | 87.88B | ||
ARGX.BR | ARGENX SE | 85.21 | 38.64B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 21.06B | ||
IDP.DE | BIOGEN INC | 8.82 | 17.76B | ||
0QF.DE | MODERNA INC | N/A | 7.97B | ||
1MRNA.MI | MODERNA INC | N/A | 7.96B | ||
1EXAS.MI | EXACT SCIENCES CORP | N/A | 7.29B |
IntegraGen SA engages in the development of genetic biomarkers. The company is headquartered in Evry, Ile-De-France and currently employs 39 full-time employees. The company went IPO on 2010-06-18. The company researches and develops biomarkers for use as diagnostic tools in the fields of autism, oncology, diabetes and obesity. The company uses an evaluation model with several autism-related genes using a combination of several common polymorphisms (Single-Nucleotide Polymorphism or SNP or common variant). The company also develops molecular biomarker validation programs for Hepatocellular Carcinoma and anti-epidermal growth factor receptor (anti-EGFR) resistance markers. The firm also provides genomics services to practitioners and researchers, such as DNA extraction, marker selection and tagging and bioinformatical analysis of sequence data in such fields as pharmacogenetics, cytogenetics, epigenetics, search for mutations and SNP discovery, among others. As of December 31, 2011, the Company operated through a wholly owned subsidiary, IntegraGen Inc.
INTEGRAGEN
Genopole Campus 1 - Genavenir 8 5 Rue Henri Desbrueres
Evry ILE-DE-FRANCE FR
Employees: 44
Phone: 33160910900
The current stock price of ALINT.PA is 0.27 EUR. The price increased by 1.5% in the last trading session.
The exchange symbol of INTEGRAGEN is ALINT and it is listed on the Euronext Paris - Matif exchange.
ALINT.PA stock is listed on the Euronext Paris - Matif exchange.
INTEGRAGEN (ALINT.PA) has a market capitalization of 1.82M EUR. This makes ALINT.PA a Nano Cap stock.
INTEGRAGEN (ALINT.PA) currently has 44 employees.
INTEGRAGEN (ALINT.PA) has a support level at 0.26 and a resistance level at 0.28. Check the full technical report for a detailed analysis of ALINT.PA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALINT.PA does not pay a dividend.
INTEGRAGEN (ALINT.PA) will report earnings on 2025-10-01.
INTEGRAGEN (ALINT.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.04).
ChartMill assigns a fundamental rating of 1 / 10 to ALINT.PA. Both the profitability and financial health of ALINT.PA have multiple concerns.
Over the last trailing twelve months ALINT.PA reported a non-GAAP Earnings per Share(EPS) of -0.04. The EPS decreased by -33.33% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -4.71% | ||
ROE | -14.77% | ||
Debt/Equity | 0.11 |